Introduction
Glucocorticoids have been used for decades in the treatment of many diseases, including acute lymphoblastic leukemia (ALL). Dexamethasone has become the preferred glucocorticoid over prednisone because of its greater antileukemic efficacy [1] [2] [3] . However, at current doses, more toxicity is observed in ALL patients treated with dexamethasone than prednisone, including infections [3] , osteonecrosis [4] , myopathy [5, 6] , and central nervous system (CNS) toxicity [7] .
Osteonecrosis is one of the most common and serious toxicities associated with ALL therapy, with frequencies ranging from 1 to 25% depending on the clinical trial [4, [8] [9] [10] [11] [12] [13] [14] . Osteonecrosis is defined as bone death resulting from poor blood supply [15] . The risk of osteonecrosis has been associated with the intensity of the glucocorticoid exposure, type of glucocorticoid (dexamethasone > prednisone) [4] , age, sex [16] , race [14] , asparaginase antibodies [17] , and genetic polymorphisms [8, [18] [19] [20] [21] . In addition, our group showed that the top single nucleotide polymorphisms (SNPs) associated with osteonecrosis were also associated with other dexamethasone-related phenotypes, including low serum albumin and high cholesterol levels [8] , and lack of allergy to asparaginase [21] . These findings suggest that a comprehensive Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
analysis of genetic predisposition to pleiotropic glucocorticoid-induced adverse effects might improve the power to identify genetic variants associated with glucocorticoid-induced osteonecrosis and other adverse effects. Moreover, the association of the same variants with multiple phenotypes, for example, osteonecrosis in addition to other phenotypes, might suggest common pathways that underlie more than one glucocorticoidinduced phenotype.
Here, we have implemented a method to use previous pharmacologic knowledge to carry out an integrated analysis of SNPs associated with pleiotropic glucocorticoidinduced biological and clinical endpoints [22] [23] [24] , with a particular focus on the clinically important phenotypes of osteonecrosis and thrombosis, both of which can necessitate major clinical interventions [25] [26] [27] [28] [29] . We compared the results of the pleiotropic analysis with those obtained with a single-phenotype genome-wide association study (GWAS) approach.
Patients and methods

Patients
Informed consent was obtained from the parents or the patient, and assent from the patient where appropriate, and the study was approved by the institutional review board. Children with newly diagnosed ALL (n = 498) were enrolled on a frontline protocol, St Jude Total XV (ClinicalTrials.gov ID NCT00137111) [29] ( Supplementary  Fig. 1 , Supplemental digital content 1, http://links.lww.com/ FPC/B227). This cohort has been reported previously in single-phenotype association studies [8, 30] .
Phenotypes
Patients were prospectively screened for osteonecrosis by MRI as described previously [8] . Toxicities were graded prospectively using the National Cancer Institute Common BMI was calculated from height and weight at day 15 of the consolidation phase of therapy. Height was measured each week and the growth trajectory was calculated using a linear fit of the change in height during the first 12 months of therapy for each patient. For each patient, the slope of the linear fit was used as the phenotype in the analysis.
Genotyping
Germline DNA was extracted from blood after remission was achieved. Genotypes were generated and calls were prepared as described [35] com/FPC/B232). The similarity of SNPs identified by these four analyses led us to focus on the PR14 analysis throughout the rest of the manuscript. The P values for each single-phenotype association statistic and the linear combination of these statistics were determined by permutation of the assignment of phenotype data to genotype data. In this study, we used the hybrid-permutation algorithm [36] to compute P values.
The P value threshold for the significance for each singlephenotype GWAS and for each pleiotropic PROMISE GWAS was determined by the profile information (I p ) criterion, which sets the P-value threshold that best balances false-positive and false-negative errors [36] . Supplementary 
Results
We identified 14 clinical phenotypes likely related to glucocorticoid effects (Supplementary Table 1 , Supplemental digital content 3, http://links.lww.com/FPC/ B229), and then tested the pairwise correlation between all combinations of the 14 phenotypes and found the expected associations (Fig. 1) . The phenotypes consisted of osteonecrosis, CNS toxicity, hyperglycemia, hypokalemia, thrombosis, plasma dexamethasone exposure, BMI, serum cortisol level, albumin levels, growth trajectory, asparaginase antibody exposure, and change in serum cholesterol, triglycerides, and low-density lipoproteins during dexamethasone treatment. The strongest associations were found between changes in serum low-density lipoprotein (LDL) and total cholesterol (P = 4.9 × 10 , Supplementary Fig. 4 , Supplemental digital content 11, http://links.lww.com/FPC/ B237). Osteonecrosis was associated with the increase in serum cholesterol during dexamethasone treatment (P = 0.0027), hyperglycemia (P = 0.01) and thrombosis (P = 0.03, Supplementary Fig. 4 , Supplemental digital content 11, http://links.lww.com/FPC/B237).
There was considerable variability in the distributions and frequencies of these phenotypes ( Supplementary  Fig. 5 , Supplemental digital content 12, http://links.lww. com/FPC/B238). Each SNP was tested for association with each phenotype in conventional single-phenotype GWAS and the PROMISE technique [22, 23] was used to select SNPs associated with pleiotropic phenotypes, weighted toward finding SNPs associated with osteonecrosis and thrombosis (the two most clinically important phenotypes) in our main analysis, termed PR14 (see Materials and methods section). A total of 610 SNPs fulfilled the PROMISE information profile (I p ) P-value threshold of less than 7.3 × 10 − 4 in the PR14 analysis (Fig 2, Supplementary  Table 3 , Supplemental digital content 7, http://links.lww.com/ FPC/B233). Five of the top 10 SNPs (Table 1) are on chromosome 12 near keratin genes; of these five, four were in linkage disequilibrium with SNPs in a glucocorticoid receptor-binding site (rs830376, rs389523, rs112746594, r 2 ≥ 0.8, Haploreg v4.1).
As expected, the top-ranked SNPs by PROMISE (PR14) included a greater number of pleiotropic SNPs than did the individual phenotype GWASs (Supplementary Table 7 Table 7 , Supplemental digital content 13, http://links.lww.com/FPC/B239). PROMISE (PR14) showed greater enrichment of SNPs predicted to be expression quantitative trait locus (eQTLs) (RegulomeDB [37] score of 1) than single-phenotype GWAS for ON, thrombosis, or CNS toxicity (P = 1.22 × 10 − 6 Fig. 3 ).
We used the RegulomeDB score to prioritize the 610 PR14 SNPs selected by the I p criterion. The top RegulomeDB score (1b) was annotated to a SNP downstream of F2RL1 (rs6453253), which was near another PR14-selected SNP in the intron of F2RL1 with a score of 1f (rs2243057, Table 2 ). Both these SNPs were in the regulatory regions indicated by H3K27 acetylation in osteoblast and HUVEC cell lines ( Supplementary Fig. 8 , Supplemental digital content 16, http://links.lww.com/FPC/B242), which were the most relevant cell lines available for the osteonecrosis phenotype. One of the F2RL1 SNPs, rs6453253, was also in a glucocorticoid receptor (NR3C1)-binding site ( Supplementary Fig. 8 , Supplemental digital content 16, http://links.lww.com/FPC/B242). The A allele of rs2243057 was associated with an increased risk of ON (P = 0.0069; Fig. 4a ) and thrombosis (P = 0.01; Fig. 4b ), with lower albumin levels (P = 0.04), and a greater increase in cholesterol (P = 0.003) and triglycerides (P = 0.0002) from week 7 to week 8 of continuation therapy (Fig. 4c-f) . The G allele of rs6453253 was also associated with an increased risk of osteonecrosis (P = 0.042), greater increase in cholesterol (P = 0.01), and higher dexamethasone exposure (P = 0.006). Both SNPs have high minor allele frequencies (MAF) of 48% in our patients and were in positive linkage disequilibrium (r 2 = 0.84). Both F2RL1 SNPs were eQTLs for F2RL1 expression in liver and whole blood, and for F2R, which encodes the receptor for thrombin, in skeletal muscle ( Supplementary Fig. 9 , Supplemental digital content 17, http://links.lww.com/FPC/B243) [38] . Circos plot of pleiotropic phenotypes. Connections shown between two phenotypes have a Spearman rank correlation P value less than 0.2. The width of the connection corresponds to the − log10(P-value) for the correlation, which is represented by numbers around the circle. The segment is faded if the correlation is inverse (e.g. higher dexamethasone AUC with lower albumin). Asp Ab AUC, asparaginase antibody area under the curve; CNS, central nervous system; Dex AUC, dexamethasone area under the curve; Growth, growth trajectory; LDL, low-density lipoproteins; ON, osteonecrosis. Detailed descriptions of the phenotypes are included in the Materials and methods section and in Supplementary Fig. 5 (Supplemental digital content 12, http://links.lww.com/FPC/B238).
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Another SNP highly ranked in the PR14 PROMISE analysis was rs10869729 in the 3′ UTR of PCSK5. This noncoding variant was associated with ON (P = 0.003), lower albumin (P = 0.003), decreased growth trajectory (P = 0.0002), and hyperglycemia (P = 0.02). Variants in this gene have been associated previously with many traits, including levels of LDL, cholesterol, and triglycerides [39] , glucose tolerance in diabetics [40] , and height [41] [42] [43] . Table 3 , Supplemental digital content 7, http://links.lww. com/FPC/B233) associated with dexamethasone pharmacokinetics, but not osteonecrosis, was rs709063, near ZNF467 and SSPO. The T allele was associated with six phenotypes with a P value of less than 0.05: increased dexamethasone AUC (P = 3.77 × 10 − 4 ), lower albumin (P = 0.008), lower asparaginase antibody AUC (P = 0.02), thrombosis (P = 0.02), CNS toxicity (P = 0.03), and hyperglycemia (P = 0.03). The ZNF467 gene encodes a cofactor that promotes adipocyte differentiation and suppresses osteoblast differentiation [44] , whereas the SSPO gene encodes a glycoprotein of the thrombospondin family secreted in the cerebrospinal fluid that interacts with LDL during brain development [45] .
An intriguing PR14 PROMISE variant (Supplementary
Using a single-phenotype GWAS with osteonecrosis as the primary phenotype, 645 SNPs were selected at the Ip threshold of P value of less than 6.4 × 10 − 4 , 49 (7.6%) of which were also selected in the PR14 PROMISE analysis (Supplementary Table 4 , Supplemental digital content 8, http://links.lww.com/FPC/B234). A single-phenotype GWAS for thrombosis showed 794 SNPs that were selected at the I p threshold of P value of less than 5.6 × 10 − 4 , 11 (1.4%) of which were also selected in the PR14 PROMISE analysis (Supplementary Table 5 , Supplemental digital content 9, http://links.lww.com/FPC/B235). There were 22 SNPs that reached the conventional GWAS P-value threshold of less than 5 × 10
. In a single-phenotype GWAS for CNS toxicity, there were 1146 SNPs selected with the information profile threshold P value of less than 5.5 × 10
, none of which were selected in the PR14 PROMISE analysis (Supplementary Table 6 , Supplemental digital content 10, http://links.lww.com/FPC/B236). This absence of overlap may be attributable to the fact that the PR14 PROMISE analysis is driven by multiple phenotypes that show a relatively weak association with CNS toxicity (Fig. 1 ). There were 38 SNPs that reached the conventional GWAS P-value threshold of less than 5 × 10 − 8 for CNS toxicity. The top two SNPs were located in an intron of the RERE gene, which encodes a nuclear receptor expressed in the brain; deficiency of this gene in a mouse model leads to abnormal brain development [46] .
Discussion
Pleiotropy, the effect of one variant on multiple traits, is commonly observed in complex diseases [47] . Cancer clinical trials, in which multiple related toxicity phenotypes are measured prospectively and genome-wide genetic analysis is carried out, provide an excellent opportunity to discover pleiotropic SNPs. Among several available methods for assessing pleiotropy [22, 23, 43, [48] [49] [50] [51] [52] , we selected the PROMISE technique, which incorporates previous biological knowledge, to identify SNPs associated with pleiotropic adverse effects of dexamethasone.
Using PROMISE, we could discover a larger number of pleiotropic SNPs for glucocorticoid effects that were in regulatory regions than we could using traditional singlephenotype GWAS. PROMISE leveraged information from multiple phenotypes that may be related to many proposed mechanisms of osteonecrosis, including intravascular thrombotic occlusion, marrow fat hypertrophy [53] [54] [55] , osteocyte and/or endothelial cell apoptosis, hypercoagulability, arteriolar occlusion through arteriopathy [56] , and vasoconstriction of specific arteries and arterioles supplying bone [57] . Dexamethasone may contribute toward osteonecrosis through its effects on lipids, coagulation, fibrinolysis, and direct toxic effects on vasculature and bone [58, 59] . It should be noted that correlations between some of these putatively related phenotypes have been observed previously [60, 61] . By accounting for pleiotropic effects, we have enhanced the probability of selecting for variants that exert their effect through common mechanisms, such as through the glucocorticoid-responsive transcriptional machinery or through systemic pharmacokinetics of dexamethasone, and might be expected to impact on multiple downstream clinical phenotypes. In contrast, we acknowledge that not all adverse effects of glucocorticoids are expected to occur by common mechanisms, and the PROMISE approach may be less able to detect such nonpleiotropic adverse drug effects than single-phenotype GWAS approaches. The fact that single-phenotype GWAS for CNS toxicity resulted in many SNPs that had genomewide significance, with no overlap with PR14 PROMISE SNPs, suggests that common mechanisms are less likely to underlie CNS toxicity and other dexamethasonerelated adverse effects. We weighted the phenotypes in the PR14 PROMISE analysis to prioritize our biological question of interest (i.e. to find genetic variants that underlie the risk of related glucocorticoid adverse effects).
Our choice of weights influenced the SNPs identified, as expected, but there was high concordance between the weighted (PR14) and unweighted (EW14) analysis ( Supplementary Fig. 3 Use of the PROMISE technique enabled us to discover variants more likely to have biological function than SNPs identified by single-phenotype GWASs (Fig. 3) . It has been shown that GWAS hits for biomedical phenotypes are enriched within regulatory regions [62, 63] . Lower RegulomeDB scores indicate that a SNP is in a regulatory region, such as a DNAse hypersensitivity site, transcription factor-binding site, promoter region, or is an eQTL [37] . SNPs associated with complex traits and pharmacologic phenotypes are more likely to be eQTLs than allele frequency-matched SNPs [64] . The A allele of F2RL1 rs2243057 is associated with pleiotropic phenotypic effects. The variants identified by PROMISE (PR14) in or near F2RL1 may be tissue-specific eQTLs for both F2RL1 (PAR2) expression and F2R (PAR1) expression. PAR1 is activated by thrombin and when thrombin binds the receptor on platelets, it stimulates clot formation. PAR2 is activated by trypsin and trypsinogen, and when activated, exerts proliferative and angiogenic effects on endothelial cells, which are key players in the arteriopathy that can initiate glucocorticoid-induced osteonecrosis in mice [56] . F2RL1 (PAR2) is expressed in bone, and F2rl1 − / − mice have reduced repair in response to bone biopsy [65] . In a meta-analysis for platelet count that included more than 44 000 individuals, a SNP in the region between the F2RL1 and F2R genes was among the top-ranked SNPs (rs17568628, P = 9.61 × 10 − 10
) [66] ; this low-frequency SNP (MAF 2.8%) was not associated with osteonecrosis or thrombosis in our cohort, but was associated with lower cortisol (P = 0.007) and albumin levels (P =0.04).
We acknowledge several limitations of our study. First, there is a lack of a similarly characterized clinical trial cohort elsewhere; thus, we lack an external replication group. Second, there may be contributions of other medications that the ALL patients receive during treatment to the phenotypes that we attribute to dexamethasone. We have attempted to minimize this limitation by including the asparaginase exposure and restricting our analysis to toxicities that are most likely associated with dexamethasone exposure (i.e. we excluded CNS toxicities likely because of methotrexate). Finally, there is currently no method to compute the power of the PROMISE procedure; thus, we have not included a power calculation for the technique.
In summary, we identified SNPs associated with the pleiotropic effects of dexamethasone that were enriched for regulatory regions of the genome. These variants may be of importance for identifying patients with underlying sensitivity to dexamethasone-induced effects before treatment.
